NASDAQ · TCMD

Tactile Systems Technology, Inc.

$27.48 +$0.04 (+0.15%) 1D Market open

Key Metrics

$618.94M
Market cap
30.49×
P/E · TTM
$343.52M
Revenue · TTM
$20.30M
Net income
EPS · TTM $0.86
Dividend yield
Free cash flow $39.23M
Beta · 1Y 0.89
EBITDA · TTM $41.07M
Gross margin 76.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 4
    From its Feb 18 high, the share price fell 32%.

    Peak close $33.05 on Feb 18; trough close $22.43 on May 4. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -32%
  • Feb 19
    The stock moved -14.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 19
  • Feb 18
    The stock moved +17.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 18

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$618.94M
Enterprise value$543.95M
Shares outstanding22.6M
52-wk range$9.60 – $37.77
Avg volume · 20D272.8K
Net cash $74.99M
Book value / share$9.19
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Tactile Systems Technology, Inc.
IPO dateJul 28, 2016
Employees1086

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E30.49
P/S1.80
P/FCF15.78
EV/EBITDA13.24
EV/Sales1.58
Graham №$13.30

Profitability

Gross 76.4%
Operating 10.0%
Net 5.9%
FCF 11.4%
ROE / ROIC 9.3% · 14.2%

Financial Health

Current ratio4.24
Quick ratio3.78
Debt / equity0.00
Debt / EBITDA 0.00Low leverage
Net cash $74.99M
Working capital$116.83M

Cash Flow · TTM

Operating CF $42.06M
Capex −$2.82M
Free cash flow $39.23M
Buybacks $17.62M
Dividends paid
Shareholder yield 2.8%

Piotroski F-Score

6 / 9
Middling fundamentals · 6 of 9 signals passing

Altman Z-Score

9.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$13.30 vs $27.48
Trades 2.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings